Review Assesses Medications for Diabetes and Osteoporosis

In people with type 2 diabetes, the risk of fracture is high. Certain diabetic medications affect bone metabolism and cause osteoporosis.

Patients with type 2 diabetes (T2D) also have osteoporosis. Managing both the conditions can be a challenge. A research team conducted a comprehensive review and identified the most effective treatment options for treating these conditions together.

The review is published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

Diabetes Drug Restriction Should Be Eased, US Panel
Experts urged the US federal to reduce the restrictions imposed on GlaxoSmithKline's controversial diabetes drug Avandia

‘Metformin, sulfonylureas, DPP-IV inhibitors and GLP-1 receptor agonists should be the preferred treatment for type 2 diabetes in adults who also have osteoporosis.’

Previous research has focused on the management of T2D and osteoporosis as separate diseases. However, several studies have shown that fracture risk is increased in people with T2D. T2D directly affects bone metabolism and strength. Certain diabetes medications affect bone metabolism, and an association exists between diabetic complications and the risk of falls and subsequent fractures.

"Metformin, sulfonylureas, DPP-4 inhibitors and GLP1 receptor agonists -- medications for T2D -- should be the preferred treatment for T2D in patients who also have osteoporosis," said the study's first author, Stavroula A. Paschou, M.D., Ph.D., of the National and Kapodistrian University of Athens in Athens, Greece.

Paschou's team prefers these medications because they can help protect bone health. Studies show that Metformin has beneficial effects on bone formation and bone mineral density. Positive or neutral effects have been seen in bone metabolism with the use of DPP-4 inhibitors and GLP1 receptor agonists.

After Cancer, Diabetes Drug may Not Improve Survival Rates
Despite previous scientific studies that suggest diabetes drug metformin has anti-cancer properties, a new study has found that the drug may not improve survival rates after breast cancer.

On the other hand, thiazolidinediones (TZDs) and canagliflozin should be avoided while other SGLT2 inhibitors are less well-validated options. Insulin should be used with caution and with careful measures to avoid hypoglycemia.

To determine the most effective treatment options, the researchers systematically reviewed past human studies and guidelines to develop recommendations for the most appropriate joint treatment approaches for diabetes and osteoporosis.

Indian Drug Major Sun Pharma Will Soon Launch a 'Diabetes Drug' in United States
Indian drug major Sun Pharmacuetical Industries Ltd said it will launch the generic version of Glumetza - a diabetes drug - soon in the United States.

A manual search of key journals and abstracts from the major annual meetings in the fields of diabetes, osteoporosis and endocrinology was also conducted. Researchers gave special attention to studies and guidelines focused on the management of patients with T2D and osteoporosis.

Paschou's team adopted a grading system introduced by the American College of Physicians. Each recommendation received two grades, one for strength (strong, weak or insufficient), and another for the quality of evidence (high, moderate or low) that supported the specific recommendation.

Diabetes Drug Tested in Patients With Parkinson's Disease
A degenerative neurological disorder marked by a progressive loss of motor control is Parkinson's disease (PD).

Based on the recommendations, researchers explain that insulin therapy is the preferred method for achieving glycemic control in patients who are hospitalized with T2D and fractures.

Paschou's team found no evidence of any detrimental effects of osteoporosis medications on glucose metabolism, but a possible beneficial effect with the use of bisphosphonates -- medications used to help prevent the loss of bone mass and treat osteoporosis. They recommend no changes to the treatment of osteoporosis because of the presence of T2D.

Researchers also note that avoiding strict targets for blood glucose levels is important for jointly managing T2D and osteoporosis for the fear of hypoglycemia, falls and fractures.

"A healthy diet and physical exercise are very important for the prevention and treatment of both conditions," said Paschou.

Source-Eurekalert